IN.PACTâ„¢ AV Access Post-Approval Study (PAS002) (NCT04543539) | Clinical Trial Compass
Active — Not RecruitingNot Applicable
IN.PACTâ„¢ AV Access Post-Approval Study (PAS002)
United States240 participantsStarted 2020-11-13
Plain-language summary
Long-term safety will be summarized
Who can participate
Age range21 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Primary Cohort Inclusion Criteria:
* Patient is ≥ 21 years of age
* Patient has a mature native AV fistula created ≥ 60 days prior to the index procedure
* Patient has a de novo and/or non-stented restenotic lesion located between the arteriovenous anastomosis and axillosubclavian junction
* Patient has a target lesion or a tandem lesion that is ≤ 100 mm in length (by visual estimate) Note: Tandem lesions may be included provided they meet all of the following criteria: a. Separated by a gap of ≤ 30 mm (3 cm), b. Total combined lesion length, including 30 mm gap, ≤ 100 mm, c. Able to be treated as a single lesion
* Patient has a target vessel diameter of 4.0 - 12.0 mm (by visual estimate)
* Patient underwent successful crossing of the target lesion with the guide wire and pre-dilatation with a PTA balloon defined as: Residual stenosis of ≤ 30% AND Absence of a flow limiting dissection or perforation AND No extravasation requiring treatment
Primary Cohort Exclusion Criteria:
* Women who are breastfeeding, pregnant, or are intending to become pregnant, or men intending to father children
* Patient is receiving immunosuppressive therapy
* Patient has an infected AV access or systemic infection
* Patient with hemodynamically significant central venous stenoses that cannot be successfully treated prior to treatment of the target lesion
* Patient with target lesion located central to the axillosubclavian junction
* Patient has significant arterial inflow lesion requiring treatme…